Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Cntx 0290

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Centrexion farms out pain drug to Lilly in deal worth up to $998M
    Centrexion farms out pain drug to Lilly in deal worth up to $998M

    29 May 2019

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/centrexion-farms-out-pain-med-to-lilly-for-47-5m-and-could-reap-much-more

    Amirah Al Idrus FIERCE BIOTECH
    29 May 2019
    Share Share
    A bruised Eli Lilly buys rights to Centrexion’s pain drug for $47.5M upfront
    A bruised Eli Lilly buys rights to Centrexion’s pain drug for $47.5M upfront

    28 May 2019

    // Natalie Grover ENDPTS

    https://endpts.com/a-bruised-eli-lilly-buys-rights-to-centrexion-early-stage-pain-drug-for-47-5m-upfront/

    Natalie Grover ENDPTS
    28 May 2019
    Share Share
    Eli Lilly In-Licenses Non-Opioid Drug from Centrexion in $997 Million-Plus Deal
    Eli Lilly In-Licenses Non-Opioid Drug from Centrexion in $997 Million-Plus Deal

    28 May 2019

    // Mark Terry BIOSPACE

    https://www.biospace.com/article/eli-lilly-in-licenses-non-opioid-compound-from-centrexion/

    Mark Terry BIOSPACE
    28 May 2019
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.